First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Enriqueta FelipVictor MorenoDaniel MorgenszternGiuseppe CuriglianoPiotr RutkowskiJosé Manuel TrigoAitana CalvoDariusz KowalskiDiego CortinovisRuth PlummerMichele MaioPaolo A AsciertoVladimir I VladimirovAndres CervantesEnrique ZudaireAnasuya HazraHuybrecht T'jollynNibedita BandyopadhyayJames G GregerEdward AttiyehHong XieEmiliano CalvoPublished in: Cancer chemotherapy and pharmacology (2022)
NCT02908906 at ClinicalTrials.gov, September 21, 2016; EudraCT 2016-002,017-22 at clinicaltrialsregister.eu, Jan 11, 2017.